The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovar...
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial
About this item
Full title
Author / Creator
Giudice, Elena , Huang, Tzu-Ting , Nair, Jayakumar R. , Zurcher, Grant , McCoy, Ann , Nousome, Darryl , Radke, Marc R. , Swisher, Elizabeth M. , Lipkowitz, Stanley , Ibanez, Kristen , Donohue, Duncan , Malys, Tyler , Lee, Min-Jung , Redd, Bernadette , Levy, Elliot , Rastogi, Shraddha , Sato, Nahoko , Trepel, Jane B. and Lee, Jung-Min
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
The multi-cohort phase 2 trial NCT02203513 was designed to evaluate the clinical activity of the CHK1 inhibitor (CHK1i) prexasertib in patients with breast or ovarian cancer. Here we report the activity of CHK1i in platinum-resistant high-grade serous ovarian carcinoma (HGSOC) with measurable and biopsiable disease (cohort 5), or without biopsiable...
Alternative Titles
Full title
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_a32a2dc2018942d5a1dda8aa8f8851d8
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a32a2dc2018942d5a1dda8aa8f8851d8
Other Identifiers
ISSN
2041-1723
E-ISSN
2041-1723
DOI
10.1038/s41467-024-47215-6
